Rexulti Tablet
Product Images NDC 59148-035

21 FDA label images from Otsuka America Pharmaceutical, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rexulti (NDC 59148-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Rexulti 01)

Chemical Structure (Rexulti 01)
Chemical structure of the active ingredient brexpiprazole, as shown in the image.*
FDA Label Image

Figure 1 (Rexulti 02)

Figure 1 (Rexulti 02)
A chart titled 'Brexpiprazole PK Measures' showing fold change and 90% confidence intervals for Cmax and AUCinf across various conditions. The conditions include renal impairment (severe), hepatic impairment (mild, moderate, severe), and population descriptions by gender and age comparisons. The horizontal axis shows change relative to reference on a logarithmic scale from 0.25 to 4, with data points and error bars indicating variability in these pharmacokinetic measures.*
FDA Label Image

Figure 2 (Rexulti 03)

Figure 2 (Rexulti 03)
A chart showing the fold change and 90% confidence intervals for brexpiprazole pharmacokinetic measures (Cmax and AUCinf) when coadministered with various inhibitors and inducers. The plot compares the change relative to the reference of brexpiprazole alone, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer rifampin, CYP2B6 inhibitor ticlopidine, and increased gastric pH via omeprazole.*
FDA Label Image

Figure 3 (Rexulti 04)

Figure 3 (Rexulti 04)
A horizontal forest plot showing fold changes and 90% confidence intervals for pharmacokinetic measures of various substrates (CYP2D6, Pgp, CYP2B6, CYP3A4, BCRP) including dextromethorphan, fexofenadine, bupropion, lovastatin, and rosuvastatin. The x-axis represents change relative to reference without interacting drug on a logarithmic scale from 0.25 to 8.*
FDA Label Image

Figure 4 (Rexulti 05)

Figure 4 (Rexulti 05)
A line graph depicting change from baseline over 6 weeks comparing ADT+Placebo and ADT+Brexpiprazole 2 mg treatment groups. The vertical axis represents change from baseline, and the horizontal axis represents weeks. Both groups show a negative change, with the Brexpiprazole 2 mg group showing a greater decrease over time.*
FDA Label Image

Figure 5 (Rexulti 06)

Figure 5 (Rexulti 06)
A line graph showing change from baseline over a period of 6 weeks for three groups: Placebo, 2 mg Brexpiprazole, and 4 mg Brexpiprazole. The vertical axis represents change from baseline, and the horizontal axis represents weeks. The graph illustrates a greater decrease in change from baseline for both Brexpiprazole doses compared to placebo over time.*
FDA Label Image

Figure 6 (Rexulti 07)

Figure 6 (Rexulti 07)
A step line graph comparing the percentage of subjects with impending relapse over time between Placebo and BREX (brexpiprazole). The vertical axis shows percentage relapse from 0% to 100%, and the horizontal axis shows days. The graph includes numbers of subjects at risk listed below the time axis for both groups.*
FDA Label Image

Figure 7 (Rexulti 08)

Figure 7 (Rexulti 08)
A line graph comparing least squares mean change from baseline (with standard error) over 6 weeks between placebo and Rexulti 2-4 mg/day treatment groups. The x-axis shows time in weeks, and the y-axis shows change from baseline. Rexulti group shows a greater decrease over time compared to placebo, with patient numbers listed below the x-axis for each week.*
FDA Label Image

Figure 8 (Rexulti 09)

Figure 8 (Rexulti 09)
Line graph depicting LS mean change from baseline (SE) over 12 weeks comparing Rexulti (2 mg/day or 3 mg/day) with placebo. The graph shows data points with error bars for both groups at multiple time intervals, illustrating the trend in change over time with patient numbers for each group noted below the x-axis.*
FDA Label Image

Principal Display Panel (0.25 mg Tablet Bottle Label)

Principal Display Panel (0.25 mg Tablet Bottle Label)
Rexulti 0.25 mg brexpiprazole tablets label for a bottle of 30 tablets. The packaging includes dosage strength, NDC 59148-035-13, and indicates prescription use only. Manufactured by Otsuka Pharmaceutical Co., distributed by Otsuka America Pharmaceutical, with additional marketing information. The label also advises keeping out of reach of children and dispensing the medication guide to each patient.*
FDA Label Image

Principal Display Panel (0.25 mg Tablet Bottle Carton)

Principal Display Panel (0.25 mg Tablet Bottle Carton)
Packaging label for Rexulti 0.25 mg tablets containing brexpiprazole. The label shows a 30-tablet carton manufactured by Otsuka America Pharmaceutical, Inc. It includes usage instructions, storage information, and cautionary statements. The design features brown, white, and yellow geometric color blocks with the Rexulti logo prominently displayed.*
FDA Label Image

Principal Display Panel (0.5 mg Tablet Bottle Label)

Principal Display Panel (0.5 mg Tablet Bottle Label)
Rexulti 0.5 mg tablets packaging label showing the brand name Rexulti with active ingredient brexpiprazole. The label indicates a count of 30 tablets with an NDC of 59148-036-13. It includes storage instructions, a barcode, and manufacturer information for Otsuka America Pharmaceutical, Inc.*
FDA Label Image

Principal Display Panel (0.5 mg Tablet Bottle Carton)

Principal Display Panel (0.5 mg Tablet Bottle Carton)
Packaging label for Rexulti 0.5 mg tablets, containing brexpiprazole as the active ingredient. The label indicates a package size of 30 tablets and includes the NDC 59148-036-13. It shows the product is manufactured by Otsuka America Pharmaceutical, Inc. The label features dosage strength, usage and storage instructions, barcode, and safety warnings.*
FDA Label Image

Principal Display Panel (1 mg Tablet Bottle Label)

Principal Display Panel (1 mg Tablet Bottle Label)
Rexulti 1 mg tablets packaging label showing 30 tablets per container. The label includes the proprietary name Rexulti and generic name brexpiprazole. It is indicated for oral use with a prescription only (Rx only). The labeler is Otsuka America Pharmaceutical, Inc., with manufacturer information from Otsuka Pharmaceutical Co., Japan. Storage instructions and NDC 59148-037-13 are also visible.*
FDA Label Image

Principal Display Panel (1 mg Tablet Bottle Carton)

Principal Display Panel (1 mg Tablet Bottle Carton)
Packaging label for Rexulti 1 mg tablets, containing brexpiprazole as the active ingredient. The label shows a 30-tablet count carton with the labeler Otsuka America Pharmaceutical, Inc. Information includes dosing guidance, storage instructions, and manufacturer details from Otsuka Pharmaceutical Co., Ltd. The label also features the NDC 59148-037-13 and a barcode.*
FDA Label Image

Principal Display Panel (2 mg Tablet Bottle Label)

Principal Display Panel (2 mg Tablet Bottle Label)
Rexulti 2 mg tablets packaging label showing a bottle containing 30 tablets of brexpiprazole. The label includes dosage strength, count, NDC 59148-038-13, and manufacturer information for Otsuka America Pharmaceutical, Inc. The label also advises dispensing the accompanying medication guide and keeping out of reach of children.*
FDA Label Image

Principal Display Panel (2 mg Tablet Bottle Carton)

Principal Display Panel (2 mg Tablet Bottle Carton)
Packaging label for Rexulti 2 mg tablets containing brexpiprazole. The label shows a carton designed to hold 30 tablets. It includes the NDC number 59148-038-13, the labeler Otsuka America Pharmaceutical, Inc., and dosage instructions. The label cautions to dispense the accompanying medication guide to patients and indicates the product is Rx only.*
FDA Label Image

Principal Display Panel (3 mg Tablet Bottle Label)

Principal Display Panel (3 mg Tablet Bottle Label)
Rexulti 3 mg tablets label showing the proprietary name Rexulti, generic name brexpiprazole, and strength 3 mg. The label indicates a package of 30 tablets, prescription only (Rx only), with storage instructions and manufacturer details from Otsuka Pharmaceutical Co. The label also includes the NDC 59148-039-13 and a barcode.*
FDA Label Image

Principal Display Panel (3 mg Tablet Bottle Carton)

Principal Display Panel (3 mg Tablet Bottle Carton)
Packaging label for Rexulti brexpiprazole tablets, 3 mg strength, with 30 tablets per bottle. The label features a purple and white design with yellow accents and includes dosage information, storage instructions, and manufacturer details for Otsuka America Pharmaceutical, Inc.*
FDA Label Image

Principal Display Panel (4 mg Tablet Bottle Label)

Principal Display Panel (4 mg Tablet Bottle Label)
Rexulti 4 mg tablets packaging label showing a blister pack containing 30 tablets. The label includes the proprietary name Rexulti, the generic name brexpiprazole, and strength 4 mg. The label also states Rx only and instructs to keep out of reach of children. Manufacturer is Otsuka Pharmaceutical Co. and the product is distributed by Otsuka America Pharmaceutical, Inc.*
FDA Label Image

Principal Display Panel (4 mg Tablet Bottle Carton)

Principal Display Panel (4 mg Tablet Bottle Carton)
Packaging label for Rexulti 4 mg brexpiprazole tablets by Otsuka America Pharmaceutical, Inc. The label features a blue, white, and yellow design with the product name, strength, dosage form, and quantity of 30 tablets. It includes NDC 59148-040-13, storage instructions, manufacturer information, and safety warnings, with a barcode on the side panel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.